Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

The companies developing new weight-loss medicines have a problem: the balance of power has shifted, and patients are bailing ...

By Michele Gershberg and Michael Erman PHILADELPHIA, March 16 (Reuters) - The CEO of Roche's Genentech unit, Ashley Magargee, ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a reduction in blood sugar levels during a late-stage ...

By Christy Santhosh March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood ...

The GLP-1 PR has been a little too good. Everyone knows the drugs lead to rapid weight loss — including participants in ...

Eli Lilly (LLY) stock trades flat as J.P. Morgan says that adverse events offset a late-stage trial win for company's ...

Patients with obesity sometimes have leptin resistance, and the "full" feeling does not get through to the brain. The new ...

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.